DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: ZEPOSIA (ozanimod)
*****************************************************
#Post#: 2162--------------------------------------------------
(Abst.) Efficacy and safety of ozanimod in MS
By: agate Date: July 26, 2018, 7:51 pm
---------------------------------------------------------
"Efficacy and safety of ozanimod in multiple sclerosis:
Dose-blinded extension of a randomized Phase II study" by from
PubMed, July 26, 2018:
HTML https://www.ncbi.nlm.nih.gov/pubmed/30043658
#Post#: 2644--------------------------------------------------
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 RADIANCE trial
By: agate Date: September 8, 2019, 8:13 pm
---------------------------------------------------------
Abstract of an article in The Lancet (September 3, 2019),
"Safety and efficacy of ozanimod vs. interferon beta-1a in
relapsing multiple sclerosis (RADIANCE): A multicentre,
randomised, 24-month, phase 3 trial":
HTML https://www.ncbi.nlm.nih.gov/pubmed/31492652
#Post#: 2645--------------------------------------------------
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 SUNBEAM trial
By: agate Date: September 8, 2019, 8:17 pm
---------------------------------------------------------
Abstract of an article in The Lancet (September 3, 2019) about a
different trial (see previous post) involving ozanimod and
interferon beta-1a--"Safety and efficacy of ozanimod vs.
interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A
multicentre, randomised, minimum 12-month, phase 3 trial":
HTML https://www.ncbi.nlm.nih.gov/pubmed/31492651
*****************************************************